CAJ | 학술논문

目的：观察利妥昔单抗联合 CHOP 方案治疗弥漫大 B 细胞淋巴瘤（DLBCL）的临床疗效。方法：分析39例2006年1月-2012年6月我院住院确诊为 DLBCL 患者的临床资料，所有患者均采用 R - CHOP 方案治疗，每3周1疗程，共4-6疗程。结果：39例患者中16例获完全缓解（ CR），CR 率为41.0%，12例获部分缓解（ PR），PR 率为30.8%，总有效率（CR + PR）为71.8%（28/39），好转（MR）和无变化（NC）各4例（10.3%），疾病进展（PD）3例（7.7%）；单因素分析发现，CR 及 PR 率与性别、年龄、ECOG 评分、结外病变数目无关（P ﹥0.05）。但与临床分期、LDH 水平、β2- MG 水平、B 细胞来源（ GCB 型、Non - GCB 型）及有无大包块病变有关（均 P ﹤0.05），患者28个月的无进展生存时间（PFS）和总生存时间（OS）分别为（54.8±5.2）%和（65.4±5.7）%。结论：利妥昔单抗联合 R - CHOP 方案治疗弥漫大 B 细胞淋巴瘤近期疗效好，不良反应轻微，可作为该病的一线治疗方案。
목적：관찰리타석단항연합 CHOP 방안치료미만대 B 세포림파류（DLBCL）적림상료효。방법：분석39례2006년1월-2012년6월아원주원학진위 DLBCL 환자적림상자료，소유환자균채용 R - CHOP 방안치료，매3주1료정，공4-6료정。결과：39례환자중16례획완전완해（ CR），CR 솔위41.0%，12례획부분완해（ PR），PR 솔위30.8%，총유효솔（CR + PR）위71.8%（28/39），호전（MR）화무변화（NC）각4례（10.3%），질병진전（PD）3례（7.7%）；단인소분석발현，CR 급 PR 솔여성별、년령、ECOG 평분、결외병변수목무관（P ﹥0.05）。단여림상분기、LDH 수평、β2- MG 수평、B 세포래원（ GCB 형、Non - GCB 형）급유무대포괴병변유관（균 P ﹤0.05），환자28개월적무진전생존시간（PFS）화총생존시간（OS）분별위（54.8±5.2）%화（65.4±5.7）%。결론：리타석단항연합 R - CHOP 방안치료미만대 B 세포림파류근기료효호，불량반응경미，가작위해병적일선치료방안。
To observe the cilinical effect of rituximab combined with CHOP chemotherapy in the treat-ment of diffuse large B - cell lymphoma. Methods:The cilinical data of 39 patients with diffuse large B - cell lympho-ma who were followed up in our hospital from 2006 to 2012 were analyzed. All patients received R - CHOP regimen of 4 - 6 cycles. Results:In all 39 patients,16(41. 0% )complete responese(CR)and 12(30. 8% )partial response (PR)were observed,the total response rate(CR + PR)was 71. 8%(28 / 39),four patients(10. 3% )got better and 4 (10. 3% )remained stable,3(7. 7% )experienced progression. By univariate analysis the parameters including clinical stage,LDH levels,β2 - Mg levels,original B - cell(GCB or Non - GCB)and bulky disease could affect the therapeu-tic effect. But gender,age,ECOG score and number of extranodal diseases had no significant effects on clinical effica-cy(P ﹥ 0. 05). The 28 - mouth progression - free survival(PFS)and overall survival(OS)were(54. 8 ± 5. 2)% and (65. 4 ± 5. 7)% ,respectively. Conclusion:R - CHOP regimen has high efficacy with mild toxicity in the treatment of diffuse large B - cell lymphoma,R - CHOP regimen can be used as the first line chemotherapy.